Stock Watch: Agios Pharma Rises On Positive Cholangiocarcinoma Trial Data

Shares of Agios Pharmaceuticals Inc. (AGIO) rose more than 18% in extended trading on Wednesday, following positive results from its global phase III trial of TIBSOVO in previously treated cholangiocarcinoma patients with an isocitrate dehydrogenase 1 (IDH1) mutation.

from RTT - Biotech http://bit.ly/30nqJef
via IFTTT